➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Colorcon
Express Scripts
McKinsey
McKesson

Last Updated: February 25, 2021

DrugPatentWatch Database Preview

Litigation Details for UNITED THERAPEUTICS CORPORATION v. WATSON LABORATORIES, INC. (D.N.J. 2015)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in UNITED THERAPEUTICS CORPORATION v. WATSON LABORATORIES, INC.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for UNITED THERAPEUTICS CORPORATION v. WATSON LABORATORIES, INC. (D.N.J. 2015)

Date Filed Document No. Description Snippet Link To Document
2016-08-08 Correct INFRINGEMENT CONTENTIONS FOR U.S. PATENT NO. 8,497,393. Motion set for 9/6/2016 before Magistrate… 18 September 2018 3:15-cv-05723 830 Patent None District Court, D. New Jersey External link to document
2017-07-27 130 Hatch-Waxman patent case involving five patents: U.S. Patent Nos. 6,521,212 (“the ’212 patent”), 6,756,033…,033 (“the ’033 patent”), 8,497,393 (“the ’393 patent”), 9,339,507 (“the ’507 patent”), and 9,358,240… the patents-in-suit, the ‘393 patent, was determined to be invalid by the United States Patent and Trial…2017. Two additional patents-in-suit, the ‘507 and ‘240 patents, are currently the subject of…resolution of two recently-filed IPRs on two of the patents-in-suit. If the stipulation and proposed order External link to document
2018-01-16 137 Hatch-Waxman patent case involving five patents: U.S. Patent Nos. 6,521,212 (“the ’212 patent”), 6,756,033…,033 (“the ’033 patent”), 8,497,393 (“the ’393 patent”), 9,339,507 (“the ’507 patent”), and 9,358,240… the patents-in-suit, the ‘393 patent, was determined to be invalid by the United States Patent and Trial…certiorari. Two additional patents-in-suit, the ‘507 and ‘240 patents, are currently the subject of… 2019. The final two patents-in-suit, the ‘212 and ‘033 patents, are set to expire on November External link to document
2016-06-21 49 seq., involving United States Patent Nos. 6,521,212 (“the ’212 patent”) (attached as Exhibit A hereto…of the ’212 patent, the ’033 patent, the ’393 patent, the ’507 patent, and the ’240 patent, inclusive…the ’212 patent, the ’033 patent, the ’393 patent, the ’507 patent, and/or the ’240 patent, including…of the ’212 patent, the ’033 patent, the ’393 patent, the ’507 patent, and the ’240 patent, inclusive…the ’212 patent, the ’033 patent, the ’393 patent, the ’507 patent, and/or the ’240 patent prior to External link to document
2016-08-05 54 Correct INFRINGEMENT CONTENTIONS FOR U.S. PATENT NO. 8,497,393 by UNITED THERAPEUTICS CORPORATION. (Attachments… 18 September 2018 3:15-cv-05723 830 Patent None District Court, D. New Jersey External link to document
2016-08-05 55 Correct INFRINGEMENT CONTENTIONS FOR U.S. PATENT NO. 8,497,393 (Attachments: # 1 Declaration of ROBERT … 18 September 2018 3:15-cv-05723 830 Patent None District Court, D. New Jersey External link to document
2016-08-12 56 supplement infringement contentions for U.S. Patent No. 8,497,393)(O'SHAUGHNESSY, WILLIAM) (Entered: 08/12… 18 September 2018 3:15-cv-05723 830 Patent None District Court, D. New Jersey External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.